携带第14外显子跳跃突变的非小细胞肺癌（NSCLC）的诊断与治疗：我们找到理想药物了吗？ - Suppr

Suppr

超能文献

Diagnosis and treatment of non-small cell lung cancer (NSCLC) harboring Ex14 skipping: have we met the desired drug?

作者信息

Makimoto Go

机构信息

Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

出版信息

Transl Lung Cancer Res. 2024 Jun 30;13(6):1438-1443. doi: 10.21037/tlcr-24-93. Epub 2024 Jun 14.

DOI:10.21037/tlcr-24-93

PMID:38973959

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11225034/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e623/11225034/e70e082833cf/tlcr-13-06-1438-f1.jpg

相似文献

Diagnosis and treatment of non-small cell lung cancer (NSCLC) harboring Ex14 skipping: have we met the desired drug?

Transl Lung Cancer Res. 2024 Jun 30;13(6):1438-1443. doi: 10.21037/tlcr-24-93. Epub 2024 Jun 14.

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.

Thorac Cancer. 2021 Mar;12(6):978-980. doi: 10.1111/1759-7714.13871. Epub 2021 Feb 3.

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.

Jpn J Clin Oncol. 2021 Aug 1;51(8):1261-1268. doi: 10.1093/jjco/hyab072.

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring exon 14 skipping mutation and high PD-L1 expression.

Drug Target Insights. 2023 Oct 6;17:110-113. doi: 10.33393/dti.2023.2626. eCollection 2023 Jan-Dec.

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report.

Case Rep Oncol. 2022 May 5;15(2):494-498. doi: 10.1159/000524326. eCollection 2022 May-Aug.

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.

Clin Cancer Res. 2022 Jan 15;28(2):249-254. doi: 10.1158/1078-0432.CCR-21-1566. Epub 2021 Aug 3.

Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.

Cancer Sci. 2024 Apr;115(4):1296-1305. doi: 10.1111/cas.16107. Epub 2024 Feb 25.

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.

Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. doi: 10.1007/s00280-022-04441-3. Epub 2022 Jun 30.

Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report.

Front Oncol. 2023 Jul 24;13:1164543. doi: 10.3389/fonc.2023.1164543. eCollection 2023.

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.

JAMA Oncol. 2023 Sep 1;9(9):1260-1266. doi: 10.1001/jamaoncol.2023.1962.

引用本文的文献

A case report of acute hepatic and renal failure associated with savolitinib treatment in advanced lung adenocarcinoma.

AME Case Rep. 2025 Mar 7;9:51. doi: 10.21037/acr-24-156. eCollection 2025.

本文引用的文献

PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.

Medicine (Baltimore). 2024 Feb 23;103(8):e36770. doi: 10.1097/MD.0000000000036770.

Clinical application of the Lung Cancer Compact Panel using various types of cytological specimens in patients with lung cancer.

Lung Cancer. 2024 Mar;189:107498. doi: 10.1016/j.lungcan.2024.107498. Epub 2024 Feb 3.

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.

Clin Lung Cancer. 2023 Sep;24(6):483-497. doi: 10.1016/j.cllc.2023.06.008. Epub 2023 Jun 18.

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.

JAMA Oncol. 2023 Sep 1;9(9):1260-1266. doi: 10.1001/jamaoncol.2023.1962.

A Prospective Validation Study of Lung Cancer Gene Panel Testing Using Cytological Specimens.

Cancers (Basel). 2022 Aug 3;14(15):3784. doi: 10.3390/cancers14153784.

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report.

Case Rep Oncol. 2022 May 5;15(2):494-498. doi: 10.1159/000524326. eCollection 2022 May-Aug.

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

Clin Lung Cancer. 2022 Jun;23(4):320-332. doi: 10.1016/j.cllc.2022.03.002. Epub 2022 Mar 17.

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.

Clin Cancer Res. 2022 Jan 15;28(2):249-254. doi: 10.1158/1078-0432.CCR-21-1566. Epub 2021 Aug 3.

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.

J Thorac Oncol. 2021 Oct;16(10):1647-1662. doi: 10.1016/j.jtho.2021.06.017. Epub 2021 Jul 8.

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.

Cancer Treat Rev. 2021 Apr;95:102173. doi: 10.1016/j.ctrv.2021.102173. Epub 2021 Mar 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验